145 related articles for article (PubMed ID: 21604021)
1. Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay.
Schott S; Wallwiener M; Kootz B; Seeger H; Fehm T; Neubauer H
Invest New Drugs; 2012 Aug; 30(4):1750-5. PubMed ID: 21604021
[No Abstract] [Full Text] [Related]
2. Pharmacologically Inactive Bisphosphonates as an Alternative Strategy for Targeting Osteoclasts: In Vivo Assessment of 5-Fluorodeoxyuridine-Alendronate in a Preclinical Model of Breast Cancer Bone Metastases.
Schem C; Tower RJ; Kneissl P; Rambow AC; Campbell GM; Desel C; Damm T; Heilmann T; Fuchs S; Zuhayra M; Trauzold A; Glüer CC; Schott S; Tiwari S
J Bone Miner Res; 2017 Mar; 32(3):536-548. PubMed ID: 27714838
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo toxicity of 5-FdU-alendronate, a novel cytotoxic bone-seeking duplex drug against bone metastasis.
Schott S; Vallet S; Tower RJ; Noor S; Tiwari S; Schem C; Busch C
Invest New Drugs; 2015 Aug; 33(4):816-26. PubMed ID: 25986684
[TBL] [Abstract][Full Text] [Related]
4. N⁴-[Alkyl-(hydroxyphosphono)phosphonate]-cytidine-new drugs covalently linking antimetabolites (5-FdU, araU or AZT) with bone-targeting bisphosphonates (alendronate or pamidronate).
Schott H; Goltz D; Schott TC; Jauch C; Schwendener RA
Bioorg Med Chem; 2011 Jun; 19(11):3520-6. PubMed ID: 21536448
[TBL] [Abstract][Full Text] [Related]
5. Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay.
Knight LA; Conroy M; Fernando A; Polak M; Kurbacher CM; Cree IA
Anticancer Drugs; 2005 Oct; 16(9):969-76. PubMed ID: 16162973
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay.
Fehm T; Zwirner M; Wallwiener D; Seeger H; Neubauer H
BMC Cancer; 2012 Jul; 12():308. PubMed ID: 22824103
[TBL] [Abstract][Full Text] [Related]
7. Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay.
Knight LA; Kurbacher CM; Glaysher S; Fernando A; Reichelt R; Dexel S; Reinhold U; Cree IA
BMC Cancer; 2009 Jan; 9():38. PubMed ID: 19175937
[TBL] [Abstract][Full Text] [Related]
8. ATP chemosensitivity testing of new antitumor duplex drugs linking 3`-C-ethynylycytidine (ECyd) and 2´-deoxy-5-fluorouridine (5-FdU) in comparison to standard cytostatica and combinations thereof.
Schott S; Wallwiener M; Kootz B; Seeger H; Fehm T; Neubauer H
Invest New Drugs; 2011 Jun; 29(3):506-13. PubMed ID: 19997962
[TBL] [Abstract][Full Text] [Related]
9. Cytostatic activity of a 5-fluoro-2'-deoxyuridine-alendronate conjugate against gastric adenocarcinoma and non-malignant intestinal and fibroblast cell lines.
Weinreich J; Schott TC; Königsrainer I; Küper M; Königsrainer A; Schott H
Anticancer Res; 2012 Oct; 32(10):4299-305. PubMed ID: 23060550
[TBL] [Abstract][Full Text] [Related]
10. In vitro toxicity of bisphosphonates on human neuroblastoma cell lines.
Vorotnjak M; Boos J; Lanvers-Kaminsky C
Anticancer Drugs; 2004 Sep; 15(8):795-802. PubMed ID: 15494642
[TBL] [Abstract][Full Text] [Related]
11. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.
Ottewell PD; Woodward JK; Lefley DV; Evans CA; Coleman RE; Holen I
Mol Cancer Ther; 2009 Oct; 8(10):2821-32. PubMed ID: 19789217
[TBL] [Abstract][Full Text] [Related]
12. Combined gossypol and zoledronic acid treatment results in synergistic induction of cell death and regulates angiogenic molecules in ovarian cancer cells.
Atmaca H; Gorumlu G; Karaca B; Degirmenci M; Tunali D; Cirak Y; Purcu DU; Uzunoglu S; Karabulut B; Sanli UA; Uslu R
Eur Cytokine Netw; 2009 Sep; 20(3):121-30. PubMed ID: 19825521
[TBL] [Abstract][Full Text] [Related]
13. Effects of capecitabine and vinorelbine on cell proliferation, metabolism and COX2 and p16 expression in breast cancer cell lines and solid tumour tissues.
Loo WT; Sasano H; Chow LW
Biomed Pharmacother; 2007 Oct; 61(9):596-600. PubMed ID: 17904787
[TBL] [Abstract][Full Text] [Related]
14. [MTT assay for detecting 5-fluorouracil chemosensitivity of human breast carcinoma cell line].
Han FX; Lin H; Ru L
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Jan; 29(1):97-9. PubMed ID: 19218124
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin cytotoxicity is enhanced with zoledronic acid in A549 lung cancer cell line: preliminary results of an in vitro study.
Ozturk OH; Bozcuk H; Burgucu D; Ekinci D; Ozdogan M; Akca S; Yildiz M
Cell Biol Int; 2007 Sep; 31(9):1069-71. PubMed ID: 17418595
[TBL] [Abstract][Full Text] [Related]
16. Selenium Nanoparticles Induce the Chemo-Sensitivity of Fluorouracil Nanoparticles in Breast and Colon Cancer Cells.
Abd-Rabou AA; Shalby AB; Ahmed HH
Biol Trace Elem Res; 2019 Jan; 187(1):80-91. PubMed ID: 29748931
[TBL] [Abstract][Full Text] [Related]
17. Potentiating bisphosphonate-based coordination complexes to treat osteolytic metastases.
Quiñones Vélez G; Carmona-Sarabia L; Rodríguez-Silva WA; Rivera Raíces AA; Feliciano Cruz L; Hu T; Peterson E; López-Mejías V
J Mater Chem B; 2020 Mar; 8(10):2155-2168. PubMed ID: 32095795
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of therapeutic efficacy of capecitabine on human breast carcinoma tissues and cell lines in vitro.
Loo WT; Sasano H; Chow LW
Biomed Pharmacother; 2007 Oct; 61(9):553-7. PubMed ID: 17905566
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of bisphosphonates on breast cancer cell lines.
Verdijk R; Franke HR; Wolbers F; Vermes I
Cancer Lett; 2007 Feb; 246(1-2):308-12. PubMed ID: 16621245
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis.
Chapurlat RD
Treat Endocrinol; 2005; 4(2):115-25. PubMed ID: 15783248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
